Poseida Therapeutics Appoints Luke Corning to Board of Directors

SAN DIEGO, Dec. 17, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Luke Corning, Portfolio Manager and Head of Credit at Pentwater Capital Management, to its Board of Directors.

“We are pleased to welcome Mr. Corning to Poseida’s Board of Directors,” said Eric Ostertag, M.D., Ph.D., and Chief Executive Officer of Poseida Therapeutics. “Luke and Pentwater have been strong supporters of Poseida and our mission since first investing in our Series C preferred stock financing and subsequently investing in our Series D financing and IPO.  His investment acumen and expertise in corporate finance complement the capabilities of our Board, as we continue to focus on advancing Poseida’s extensive pipeline of cell and gene therapies currently in development.”